By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


MabVax Therapeutics, Inc. 

11588 Sorrento Valley Road
Suite 20
San Diego  California  92121  U.S.A
Phone: 858-259-9405 Fax:



Company News
MabVax Therapeutics Announces The Closing Of Its Public Offering 8/22/2016 7:22:27 AM
MabVax Therapeutics Announces Uplisting To The Nasdaq Capital Market And $8.625 Million Public Offering 8/17/2016 6:45:21 AM
MabVax Therapeutics Initiates Patient Enrollment In A Phase I Trial For A New Diagnostic Imaging Product For Pancreatic Cancer 7/18/2016 6:32:45 AM
MabVax Therapeutics Launches Second Investigational Site With Sarah Cannon Research Institute In Ongoing Phase I Clinical Trial To Evaluate New Treatment For Pancreatic Cancer 6/14/2016 11:50:16 AM
MabVax Therapeutics Expands Patient Enrollment In Phase I Trial For Treatment Of Pancreatic Cancer To Memorial Sloan-Kettering Cancer Center 6/7/2016 8:29:17 AM
MabVax Therapeutics' Antibody Discovery Platform And Humab-5B1 Cancer Therapeutic Featured In Presentation At America's Antibody Congress 5/19/2016 9:59:06 AM
MabVax Therapeutics' HuMab-5B1 Cancer Therapeutic Featured In Presentation At AACR Special Meeting On Pancreatic Cancer 5/16/2016 7:03:41 AM
MabVax Therapeutics' Fully Human Antibody Approach To Cancer Therapeutics And Imaging Featured In Three Presentations At AACR Annual Meeting In New Orleans 4/18/2016 8:12:10 AM
MabVax Therapeutics Hires Paul Resnick, M.D. As Chief Business Officer 4/15/2016 6:17:10 AM
MabVax Therapeutics, Inc. Initiates Phase I Trial Of Humab-5B1 For Treatment Of Pancreatic Cancer 3/21/2016 6:18:28 AM